Latest:
Dr Riess on Sequencing Considerations for KRAS and BRAF Inhibitors in NSCLC
Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jonathan S. Berek, MD
Latest:
Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian Cancer
Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.
Jonathan W. Goldman, MD
Jonathan W. Goldman, MD, is a professor of medicine in the Hematology/Oncology Division, director of Clinical Trials in Thoracic Oncology, and associate director of Early Drug Development at UCLA Medical Center in California.
Latest:
Telisotuzumab Vedotin Shakes Up Management of Pretreated, c-MET–Overexpressing NSCLC: With Jonathan W. Goldman, MD
Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET protein–overexpressing, nonsquamous, EGFR wild-type NSCLC.
Jonathan W. Riess, MD, MS, UC Davis Comprehensive Cancer Center
Latest:
Experts on the Management of Diarrhea Associated With EGFR TKIs
Zosia Piotrowska, MD, Jonathan Riess, MD, MS, Gregory Riely, MD, Emily Skotte, MSN, APRN, ACNP-BC, and Amanda Cass, PharmD, BCPS, discuss the management of diarrhea as an adverse effect associated with EGFR TKIs.